Newron Pharmaceuticals SpA achieved revenue of €2.4 million in 2015, an increase of 53% from a year earlier as the result of the approval and successful launch in Europe of its lead product for Parkinson’s disease Xadago (safinamide). ---Subscribe to MedNous to access this article--- Company News
